Yubo International Biotech Ltd (YBGJ)
0.0905
-0.04
(-32.86%)
USD |
OTCM |
Nov 14, 13:05
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 10.84M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -61.38% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 23.80 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.25% |
Profile
Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform. |
URL | http://www.yubogroup.com |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | |
Industry | |
Equity Style | N/A |
Next Earnings Release | Nov. 20, 2024 (est.) |
Last Earnings Release | Aug. 19, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform. |
URL | http://www.yubogroup.com |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | |
Industry | |
Equity Style | N/A |
Next Earnings Release | Nov. 20, 2024 (est.) |
Last Earnings Release | Aug. 19, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |